Myocarditis After BNT162b2 and mRNA-1273 Vaccination

Circulation. 2021 Aug 10;144(6):506-508. doi: 10.1161/CIRCULATIONAHA.121.055913. Epub 2021 Jun 16.

¹ Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (K.F.L., G.O., D.R.H., D.D.B.).
² De Gasperis Cardio Center, Niguarda Hospital, Milano, Italy (E.A., C.C., F.O.).
³ Department of Cardiology, University of California-San Diego (E.D.A., K.N.H.).
⁴ Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL (L.T.C.).
⁵ Department of Cardiovascular and Thoracic Sciences, Fondazione Policlinico Universitario A. Gemelli Istituto di Ricovero e Cura a Carattere Scientifico, Roma, Italy (G.S., T.S.).
⁶ United Heart and Vascular Center, St Paul, MN (D.C.).
⁷ Cardiovascular Department, Association Socio Sanitary Territorial Santi Paolo e Carlo, Milano, Italy (A.C.).
⁸ Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University, Chieti, Italy (A.P.).
⁹ Department of Cardiology, Pugliese-Ciaccio Hospital, Catanzaro, Italy (V.A.C.).

Abstract

Supplemental Digital Content is available in the text.

Keywords: BNT162 vaccine; COVID-19; COVID-19 vaccines; SARS-CoV-2; mRNA-1273 vaccine; myocarditis.